Search Result

Results for "

ADHD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adrenergic Receptor (12) Apoptosis (2) Autophagy (2) Caspase (2) Cholinesterase (ChE) (2) COX (2) Dopamine Receptor (4) Dopamine Transporter (1) HDAC (1) Histamine Receptor (3) iGluR (1) Interleukin Related (2) Isotope-Labeled Compounds (2) mGluR (1) Mitophagy (2) Monoamine Transporter (1) nAChR (4) p38 MAPK (2) PGE synthase (2) Phosphodiesterase (PDE) (1) Serotonin Transporter (3) Sodium Channel (3)
By Research Areas:	Cancer (5) Cardiovascular Disease (3) Endocrinology (9) Inflammation/Immunology (2) Neurological Disease (28)

By Targets:

5-HT Receptor (2)

Adrenergic Receptor (12)

Apoptosis (2)

Autophagy (2)

Caspase (2)

Cholinesterase (ChE) (2)

COX (2)

Dopamine Receptor (4)

Dopamine Transporter (1)

HDAC (1)

Histamine Receptor (3)

iGluR (1)

Interleukin Related (2)

Isotope-Labeled Compounds (2)

mGluR (1)

Mitophagy (2)

Monoamine Transporter (1)

nAChR (4)

p38 MAPK (2)

PGE synthase (2)

Phosphodiesterase (PDE) (1)

Serotonin Transporter (3)

Sodium Channel (3)

By Research Areas:

Cancer (5)

Cardiovascular Disease (3)

Endocrinology (9)

Inflammation/Immunology (2)

Neurological Disease (28)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14880B

Bavisant dihydrochloride hydrate JNJ31001074AAC; JNJ31001074 dihydrochloride hydrate	Histamine Receptor	Neurological Disease Endocrinology
Bavisant dihydrochloride hydrate (JNJ31001074AAC) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H₃ receptor. Bavisant dihydrochloride hydrate can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-14880

Bavisant JNJ-31001074	Histamine Receptor	Neurological Disease Endocrinology
Bavisant (JNJ-31001074) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H₃ receptor. Bavisant can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-107481

Fasoracetam NS 105	mGluR	Neurological Disease
Fasoracetam (NS 105) is the activator of metabotropic glutamate receptor (mGluR). Fasoracetam (NS 105) has the potential for the research of attention-deficit hyperactivity disorder (ADHD) and Alzheimer's disease (AD) .

HY-13458

Droxidopa L-DOPS; DOPS; SM5688	Adrenergic Receptor	Neurological Disease
Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .

HY-139897

CX 717	iGluR	Neurological Disease
CX 717 is a positive allosteric modulator of AMPA receptor. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD) .

HY-14880A

Bavisant dihydrochloride JNJ-31001074 dihydrochloride	Histamine Receptor	Neurological Disease Endocrinology
Bavisant (JNJ-31001074) dihydrochloride is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H₃ receptor. Bavisant dihydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-14824A

Sofinicline benzenesulfonate ABT 894 benzenesulfonate	nAChR	Neurological Disease
Sofinicline benzenesulfonate (ABT 894 benzenesulfonate) is a novel nicotinic acetylcholine receptor agonist, specifically acting on the α4β2 subtype of nAChR (IC₅₀=0.1 nM). Sofinicline benzenesulfonate has the potential to improve cognitive function, including attention, memory and working memory. Sofinicline benzenesulfonate can be used in studies of attention deficit, hyperactivity disorder (ADHD) .

HY-13458A

Droxidopa hydrochloride L-DOPS hydrochloride; DOPS hydrochloride; SM5688 hydrochloride	Adrenergic Receptor	Neurological Disease
Droxidopa (L-DOPS) hydrochloride is a potent, orally active norepinephrine precursor. Droxidopa hydrochloride increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa hydrochloride has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .

HY-13458R

Droxidopa (Standard)	Adrenergic Receptor	Neurological Disease
Droxidopa (Standard) is the analytical standard of Droxidopa. This product is intended for research and analytical applications. Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .

HY-17416S2

Guanfacine-13C,d5 hydrochloride	Adrenergic Receptor Isotope-Labeled Compounds	Cardiovascular Disease Endocrinology
Guanfacine- ¹³C,d₅ hydrochloride is the deuterium and ¹³C labeled Guanfacine hydrochloride (HY-17416). Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-B0949

Protriptyline hydrochloride 3 Publications Verification	Cholinesterase (ChE)	Neurological Disease
Protriptyline hydrochloride is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD.

HY-U00371

AR-08	Adrenergic Receptor	Neurological Disease Endocrinology
AR-08 is an agonist of α2-adrenergic receptor, used for the treatment of attention deficit hyperactivety disorder (ADHD).

HY-14824

Sofiniclin ABT 894	nAChR	Neurological Disease
Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD) .

HY-17416AS

Guanfacine-13C,15N3	Adrenergic Receptor	Neurological Disease
Guanfacine- ¹³C, ¹⁵N₃ is the ¹³C and ¹⁵N labeled Guanfacine[1]. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[2][3][4].

HY-U00280

Potassium Channel Activator 1	Others	Neurological Disease
Potassium Channel Activator 1 is an agent for treating, one or more disorders or conditions wherein the dopaminergic system is disrupted, such as one or more disorders or conditions independently selected from the group consisting of: schizophrenia and other psychotic states; mood disorders ADHD; aggression; movement disorders.

HY-B0949S

Protriptyline (N-methyl-d3) (hydrochloride)	Cholinesterase (ChE)	Neurological Disease
Protriptyline (N-methyl-d₃) (hydrochloride) is the deuterium labeled Protriptyline hydrochloride. Protriptyline hydrochloride is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD. Unique among the TCAs, protriptyline tends to be energizing instead of sedating, used for narcolepsy to achieve a wakefulness-promoting effect[1].

HY-17385

Atomoxetine hydrochloride 4 Publications Verification Tomoxetine hydrochloride; (R)-Tomoxetine hydrochloride; LY 139603	Adrenergic Receptor Serotonin Transporter Sodium Channel	Neurological Disease Cancer
Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with K_i values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na ⁺ channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-110168

NS 9283	nAChR	Neurological Disease
NS9283 is a positive positive allosteric modulator of (α4)₃(β2)₂ nicotinic ACh receptors. NS9283 can be used in a series of neurological conditions such as attention deficit hyperactivity disorder (ADHD), schizophrenia, Parkinson's disease and Alzheimer's disease .

HY-17416A

Guanfacine	Adrenergic Receptor	Neurological Disease Endocrinology
Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-17416

Guanfacine hydrochloride 2 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-107370

Atomoxetine Tomoxetine; (R)-Tomoxetine	Serotonin Transporter Sodium Channel	Neurological Disease
Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with K_i values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DA_EX and NE_EX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na ⁺ channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-17385R

Atomoxetine hydrochloride (Standard)	Adrenergic Receptor Serotonin Transporter Sodium Channel	Neurological Disease Cancer
Atomoxetine (hydrochloride) (Standard) is the analytical standard of Atomoxetine (hydrochloride). This product is intended for research and analytical applications. Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with Ki values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na+ channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .

HY-17416R

Guanfacine hydrochloride (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Guanfacine (hydrochloride) (Standard) is the analytical standard of Guanfacine (hydrochloride). This product is intended for research and analytical applications. Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-B1081

Oxidopamine hydrochloride Maximum Cited Publications 17 Publications Verification 6-Hydroxydopamine Hydrochloride	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-19348

Pimelic Diphenylamide 106 4 Publications Verification RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII	HDAC Monoamine Transporter	Neurological Disease Cancer
Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC₅₀ values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing VMAT2 expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD) .

HY-B1081A

Oxidopamine hydrobromide Maximum Cited Publications 17 Publications Verification 6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-17416AS1

Guanfacine-15N3,13C2	Adrenergic Receptor Isotope-Labeled Compounds	Neurological Disease Endocrinology
Guanfacine- ¹⁵N₃, ¹³C₂ is ¹⁵N and ¹³C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-128420

Lobeline sulfate α-Lobeline sulfate; L-Lobeline sulfate	nAChR Dopamine Transporter	Neurological Disease
Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation .

HY-109112

Brilaroxazine RP5063	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-109112R

Brilaroxazine (Standard)	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (Standard) is the analytical standard of Brilaroxazine. This product is intended for research and analytical applications. Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-101490

PDE1-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC₅₀ values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-128420

Lobeline sulfate α-Lobeline sulfate; L-Lobeline sulfate	Alkaloids Structural Classification other families Source classification Pyridine Alkaloids Plants Endogenous metabolite	nAChR Dopamine Transporter
Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation .

Cat. No.	Product Name	Chemical Structure

HY-17416S2

Guanfacine-13C,d5 hydrochloride
Guanfacine- ¹³C,d₅ hydrochloride is the deuterium and ¹³C labeled Guanfacine hydrochloride (HY-17416). Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

Guanfacine-13C,d5 hydrochloride

Guanfacine- ¹³C,d₅ hydrochloride is the deuterium and ¹³C labeled Guanfacine hydrochloride (HY-17416). Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-17416AS

Guanfacine-13C,15N3
Guanfacine- ¹³C, ¹⁵N₃ is the ¹³C and ¹⁵N labeled Guanfacine[1]. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[2][3][4].

Guanfacine-13C,15N3

Guanfacine- ¹³C, ¹⁵N₃ is the ¹³C and ¹⁵N labeled Guanfacine[1]. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[2][3][4].

HY-B0949S

Protriptyline (N-methyl-d3) (hydrochloride)
Protriptyline (N-methyl-d₃) (hydrochloride) is the deuterium labeled Protriptyline hydrochloride. Protriptyline hydrochloride is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD. Unique among the TCAs, protriptyline tends to be energizing instead of sedating, used for narcolepsy to achieve a wakefulness-promoting effect[1].

HY-17416AS1

Guanfacine-15N3,13C2
Guanfacine- ¹⁵N₃, ¹³C₂ is ¹⁵N and ¹³C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

Guanfacine-15N3,13C2

Guanfacine- ¹⁵N₃, ¹³C₂ is ¹⁵N and ¹³C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks